| Not Yet Recruiting | Evaluation of the Quality of Life in Patients With Chronic Iron Overload Due to Hemoglobinopathies in Greece. NCT07352878 | Elpen Pharmaceutical Co. Inc. | — |
| Recruiting | A Real-World Study to Evaluate Luspatercept in Adults With Transfusion-Dependent Beta-Thalassemia in the Middl NCT07215975 | Bristol-Myers Squibb | — |
| Completed | A Study on the Effect of Etavopivat on Heart Rhythm in Healthy Participants NCT07023029 | Novo Nordisk A/S | Phase 1 |
| Recruiting | A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassa NCT06609226 | Novo Nordisk A/S | Phase 3 |
| Recruiting | Effect of Exercise on Body Composition and Bone Health in Patients With Thalassemia NCT07064941 | University of California, San Francisco | N/A |
| Active Not Recruiting | Development of THALEA Kit and Its Impact on Knowledge, Attitude, and Intention for Premarital Thalassemia Scre NCT06800495 | Universiti Teknologi Mara | N/A |
| Completed | A Research Study Looking at a Single Dose of Etavopivat in Healthy Chinese Participants NCT06581627 | Novo Nordisk A/S | Phase 1 |
| Not Yet Recruiting | Effect of Folic Acid Supplementation in Pregnant Women Having Thalassaemia Trait NCT04310059 | The University of Hong Kong | N/A |
| Not Yet Recruiting | EKLF Gene Expression in β-thalassemia NCT06440603 | Rofaida Hassan Ahmed | — |
| Recruiting | Evaluating Safety and Efficacy of Lentiviral-transduced CD34+ HSCs in Β-thalassaemia Patients. NCT06655662 | Shenzhen Hemogen | Phase 1 |
| Recruiting | A Study of Safety and Efficiency of AND017 in Patients With β-thalassemia NCT06302491 | Kind Pharmaceuticals LLC | Phase 2 |
| Completed | Impact of Virtual Reality on Pain and Anxiety During Intravenous Cannulation Procedures Among Thalassemia Pati NCT07099196 | Mohammed Bin Rashid University of Medicine and Health Sciences | N/A |
| Recruiting | Determination of Red Cell Survival in Sickle Cell Disease and Other Hemoglobinopathies Using Biotin Labeling NCT06313398 | National Heart, Lung, and Blood Institute (NHLBI) | EARLY_Phase 1 |
| Recruiting | A Phase 1 Study of Gene-modified Autologous Hematopoietic Stem Cell (BD211) Treating β-thalassemia Major NCT06465550 | Shanghai BDgene Co., Ltd. | Phase 1 |
| Unknown | Assessment of Cognitive Function and Quality of Life in Thalassemic Children at Sohag University Hospital NCT06058260 | Sohag University | — |
| Recruiting | Safety and Efficacy of Gene Modified Autologous Hematopoietic Stem Cells to Treat Transfusion-dependent Beta-t NCT05773729 | Shanghai BDgene Co., Ltd. | N/A |
| Completed | Effect of L-Glutamine on Pulmonary Artery Pressure in Patients With Non-Transfusion-Dependent Thalassemia NCT07210450 | Mazandaran University of Medical Sciences | Phase 2 / Phase 3 |
| Completed | Pregnancy and Childbirth in Women with Thalassemia Yesterday and Today NCT06889727 | Fondazione per la Ricerca sulle Anemie ed Emoglobinopatie in Italia | — |
| Completed | Safety and Efficacy of Immunomodulator Drug Thalidomide in Multi-transfused Thalassemia Patients NCT06888232 | Muhammad Aamir Latif | N/A |
| Unknown | Assessment of Quality of Life in Thalassemic Patients at Assiut University Hospital: A Single-center Experienc NCT05790980 | Assiut University | — |
| Completed | Pharmacotherapy Prescribing Pattern and the Adherence Level to Iron Chelation Therapy in Thalassemia NCT06210139 | Reem Ali Shaker | — |
| Recruiting | A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to NCT05736419 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Recruiting | the Safety and Efficacy Evaluation of HGI-002 Injection in Patients With Transfusion-Dependent α-Thalassemia NCT05851105 | Shenzhen Hemogen | EARLY_Phase 1 |
| Recruiting | Atrial Fibrillation in Beta-Thalassemia NCT05508932 | University Hospital of Ferrara | — |
| Recruiting | Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thal NCT05477563 | Vertex Pharmaceuticals Incorporated | Phase 3 |
| Unknown | Correlation Between Pulmonary Functions and Physical Fitness in Children With β-thalassemia NCT05494333 | Cairo University | — |
| Recruiting | European Rare Blood Disorders Platform (ENROL) NCT06250595 | Hospital Universitari Vall d'Hebron Research Institute | — |
| Completed | Long-term Clinical Study of CN128 in Thalassemia With Sever Liver Iron Overloaded Patients NCT05355766 | Hangzhou Zede Pharma-Tech Co., Ltd. | Phase 2 |
| Completed | Inhibitory Effect of a Polyphenol Supplement on Dietary Iron Absorption in Adults with Thalassemia NCT05326503 | Swiss Federal Institute of Technology | N/A |
| Recruiting | the Safety and Efficacy Evaluation of HGI-001 Injection in Patients With Transfusion-Dependent β-Thalassemia NCT05864170 | Shenzhen Hemogen | EARLY_Phase 1 |
| Active Not Recruiting | Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia NCT05356195 | Vertex Pharmaceuticals Incorporated | Phase 3 |
| Completed | A Study of Etavopivat in Patients With Thalassemia or Sickle Cell Disease NCT04987489 | Forma Therapeutics, Inc. | Phase 2 |
| Completed | Red Blood Cell - IMProving trAnsfusions for Chronically Transfused Recipients NCT05255445 | Westat | — |
| Recruiting | RADeep Multicenter European Epidemiological Platform for Patients Diagnosed With Rare Anemia Disorders (RADs) NCT06213402 | Hospital Universitari Vall d'Hebron Research Institute | — |
| Unknown | Thalassemia Knowledge in Young People of Indonesia NCT04706585 | Fakultas Kedokteran Universitas Indonesia | — |
| Enrolling By Invitation | A Long-term Follow-up Study in Participants Who Received CTX001 NCT04208529 | Vertex Pharmaceuticals Incorporated | Phase 3 |
| Recruiting | Safety and Efficacy Evaluation of β-globin Restored Autologous Hematopoietic Stem Cells in β-thalassemia Major NCT05745532 | Shenzhen Hemogen | EARLY_Phase 1 |
| Terminated | A Study of IMR-687 in Subjects With Beta Thalassemia NCT04411082 | Cardurion Pharmaceuticals, Inc. | Phase 2 |
| Completed | Assessment of Nutritional Status and Role of Insulin-like Growth Factor-1 in Children NCT05529550 | Menoufia University | — |
| Completed | Long-term Clinical Study of CN128 in Thalassemia Patients NCT04614779 | Hangzhou Zede Pharma-Tech Co., Ltd. | Phase 2 |
| Recruiting | ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders NCT04398628 | American Thrombosis and Hemostasis Network | — |
| Completed | The Role of OCTA in Patients Affected by Beta Thalassemia NCT04582110 | Federico II University | — |
| Terminated | Hydroxyurea Therapy: Optimizing Access in Pediatric Populations Everywhere NCT03825341 | St. Jude Children's Research Hospital | Phase 2 |
| Completed | Safety Study for Beta Thalassemia Subjects on PTG-300 NCT04054921 | Protagonist Therapeutics, Inc. | Phase 2 |
| Active Not Recruiting | A Study to Determine the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of AG-348 in Adult Participa NCT03692052 | Agios Pharmaceuticals, Inc. | Phase 2 |
| Active Not Recruiting | A Blood Stem Cell Transplant for Sickle Cell Disease NCT03249831 | City of Hope Medical Center | Phase 1 |
| Unknown | iHSCs With the Gene Correction of HBB Intervent Subjests With β-thalassemia Mutations NCT03728322 | Allife Medical Science and Technology Co., Ltd. | EARLY_Phase 1 |
| Completed | Study of PTG-300 in Non-Transfusion Dependent and Transfusion-Dependent Beta-Thalassemia Subjects With Chronic NCT03802201 | Protagonist Therapeutics, Inc. | Phase 2 |
| Completed | Short-term Clinical Study of CN128 in Thalassemia Patients NCT03935633 | Hangzhou Zede Pharma-Tech Co., Ltd. | Phase 1 |
| Completed | A Safety and Efficacy Study Evaluating CTX001 in Participants With Transfusion-Dependent β-Thalassemia NCT03655678 | Vertex Pharmaceuticals Incorporated | Phase 2 / Phase 3 |
| Completed | Adiponectin, IL-6 and hsC-RP in Relation to Carotid Intima-media Thickness in B-thalassemia Patients NCT03170245 | Assiut University | — |
| Completed | Cerebrovascular Reserve and White Matter Disease in Patients with Chronic Anemia NCT03715972 | Children's Hospital Los Angeles | — |
| Terminated | Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation (HaploHCT) Following Reduced Intensity Condi NCT03367546 | Masonic Cancer Center, University of Minnesota | Phase 2 |
| Completed | Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell Transplantation NCT03513328 | University of Florida | Phase 1 / Phase 2 |
| Completed | Immunomodulatory Vitamin D in Thalassemia NCT03919812 | Universitas Padjadjaran | N/A |
| Unknown | Colla Corii Asini Treating Anemia in Pregnant Women With Thalassemia(Presenting the Syndrome of Blood Deficien NCT03374111 | The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine | Phase 4 |
| Completed | A Study to Determine the Efficacy and Safety of Luspatercept in Adults With Non Transfusion Dependent Beta (β) NCT03342404 | Celgene | Phase 2 |
| Completed | Clinical Study of CN128 in Thalassemia Patients NCT03673085 | Hangzhou Zede Pharma-Tech Co., Ltd. | Phase 1 |
| Completed | Efficacy and Safety of Low Dose Thalidomide in Transfusion Dependent Thalassemia NCT03651102 | Blood Diseases Clinic | Phase 2 / Phase 3 |
| Terminated | Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Pa NCT03333486 | Roswell Park Cancer Institute | Phase 2 |
| Unknown | Study on the Mechanism of Colla Corri Asini in the Treatment of Thalassemia Patients With Pregnancy Anemia NCT03392298 | The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine | Phase 4 |
| Unknown | Quality of Life and Treatment Satisfaction in β-Thalassemia Patients Receiving Deferasirox NCT03358498 | Assiut University | — |
| Completed | Study of Thiotepa and TEPA Drug Exposure in Pediatric Hematopoietic Stem Cell Transplant Patients NCT03609840 | University of California, San Francisco | — |
| Completed | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 702843 Administered Subcutaneously to Hea NCT03165864 | Ionis Pharmaceuticals, Inc. | Phase 1 |
| Unknown | The Effective and Safety of Thalidomide in TI NCT03184844 | Xiao-Lin Yin | Phase 2 |
| Completed | Sofosbuvir/Ledipasvir for Hepatitis C Genotype 1-6 in Patients With Transfusion-Dependent Thalassemia: An Open NCT03032666 | Ala'a Sharara | Phase 4 |
| Completed | Hemoglobinopathy Nursing Program and Pediatric Nursing Students NCT05389891 | Beni-Suef University | N/A |
| Terminated | Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study NCT03733249 | Bellicum Pharmaceuticals | Phase 1 / Phase 2 |
| Unknown | The Effective and Safety of Thalidomide in NTDT NCT02995707 | Xiao-Lin Yin | Phase 2 |
| Unknown | L-arginine Versus Sildenafil in Children With Beta Thalassemia Associated With Pulmonary Hypertension NCT03402191 | Sherief Abd-Elsalam | Phase 4 |
| Terminated | Allogeneic SCT of CordIn™, in Patients With Hemoglobinopathies NCT02504619 | Gamida Cell ltd | Phase 1 / Phase 2 |
| Completed | Study of Clofarabine and Fludarabine Drug Exposure in Pediatric Bone Marrow Transplantation (HCT) NCT03609814 | University of California, San Francisco | — |
| Completed | The Prevalence and Severity of HCV Infection in Thalassemia Major and Thalassemia Intermedia in Siriraj Hospit NCT02904252 | Mahidol University | — |
| Completed | Study of Melphalan Drug Exposure in Pediatric Hematopoietic Stem Cell Transplant Patients NCT03609827 | University of California, San Francisco | — |
| Active Not Recruiting | CINC424A2X01B Rollover Protocol NCT02386800 | Novartis Pharmaceuticals | Phase 4 |
| Unknown | Therapeutic Effect of Colla Corii Asini on Improving Anemia and Hemoglobin Composition in Pregnant Women With NCT02772016 | Yanfang Li | EARLY_Phase 1 |
| Completed | Haploidentical Hematopoietic Stem Cell Transplantation NCT02165007 | Catherine Bollard | Phase 1 |
| Completed | Extension Study to Evaluate the Safety and Efficacy of Luspatercept in Participants With β-Thalassemia Previou NCT02268409 | Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA | Phase 2 |
| Completed | Use of Mobile Technology for Intensive Training in Medication Management NCT02133560 | Duke University | N/A |
| Active Not Recruiting | Nonmyeloablative Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disea NCT02105766 | National Heart, Lung, and Blood Institute (NHLBI) | Phase 2 |
| Terminated | Safety Study of Gene Modified Donor T-cells Following TCRαβ+ Depleted Stem Cell Transplant NCT02065869 | Bellicum Pharmaceuticals | Phase 1 / Phase 2 |
| Completed | Amlodipine for Myocardial Iron in Thalassemia NCT02065492 | Aga Khan University | Phase 2 / Phase 3 |
| Unknown | A Case Control Study to Evaluate the Cognitive and Brain Function of β-thalassemia Patients. NCT01935661 | HaEmek Medical Center, Israel | — |
| Completed | Pneumococcal Vaccination for Splenectomised Thalassemia Major Patients in Indonesia NCT03095326 | Fakultas Kedokteran Universitas Indonesia | Phase 4 |
| Completed | Zinc Supplementation on Cellular Immunity in Thalassemia Major NCT03117192 | Fakultas Kedokteran Universitas Indonesia | Phase 4 |
| Completed | Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders NCT01758042 | Massachusetts General Hospital | N/A |
| Completed | Zinc and Diabetes in Patients With Thalassemia: a Pilot Study NCT01772680 | UCSF Benioff Children's Hospital Oakland | N/A |
| Completed | Amlodipine in the Prevention and Treatment of Iron Overload in Patients With Thalassemia Major NCT01395199 | University of Campinas, Brazil | Phase 3 |
| Completed | Multicenter Observational Study on Myocardial Iron Overload in 3 Multitransfused Populations NCT01911871 | Assistance Publique - Hôpitaux de Paris | — |
| Terminated | Effects of Transfusion of Older Stored Red Cells NCT01534676 | Columbia University | N/A |
| Completed | Demographic, Clinical, Laboratory and Genetical Characteristics of Patients With Beta Thalassemia Intermedia NCT01443312 | HaEmek Medical Center, Israel | — |
| Completed | Study of Effects of YisuiShengxueGranules on Thalassemia NCT01549080 | Guang'anmen Hospital of China Academy of Chinese Medical Sciences | — |
| Withdrawn | Phase I/II Pilot Study of Mixed Chimerism to Treat Hemoglobinopathies NCT01419704 | Talaris Therapeutics Inc. | Phase 1 / Phase 2 |
| Completed | Renal Function Among Thalassemia Patients Treated by a Oral Chelator Deferasirox NCT01905774 | HaEmek Medical Center, Israel | — |
| Completed | Study of Fludarabine Drug Exposure in Pediatric Bone Marrow Transplantation NCT01316549 | University of California, San Francisco | — |
| Completed | Genes Influencing Iron Overload State NCT01158794 | St. Jude Children's Research Hospital | — |
| Terminated | Alefacept and Allogeneic Hematopoietic Stem Cell Transplantation NCT01319851 | Emory University | N/A |
| Completed | Multi-Center Study of Iron Overload: Survey Study (MCSIO) NCT01913548 | UCSF Benioff Children's Hospital Oakland | — |
| Completed | Efficacy and Safety of Desferal Versus Osveral in Transfusional Iron Overload NCT01369719 | Hormozgan University of Medical Sciences | N/A |
| Completed | This Study Will Evaluate Efficacy and Safety of Deferasirox in Patients With Myelodysplastic Syndromes (MDS), NCT01250951 | Novartis Pharmaceuticals | Phase 4 |
| Completed | Multi-Center Study of Iron Overload: Pilot Study NCT01114776 | UCSF Benioff Children's Hospital Oakland | — |
| Completed | Assessment of Pain in People With Thalassemia Who Are Treated With Regular Blood Transfusions NCT00872833 | Carelon Research | — |
| Completed | Effect of Antioxidant Cocktail in Beta-thalassemia/Hb E Patients NCT01597765 | Mahidol University | N/A |
| Completed | Blood Transfusions in Thalassemia Patients, Complications and Adverse Effects NCT00971880 | HaEmek Medical Center, Israel | — |
| Completed | Glutamine Therapy for Hemolysis-Associated Pulmonary Hypertension NCT01048905 | UCSF Benioff Children's Hospital Oakland | Phase 2 |
| Completed | Allo-HCT MUD for Non-malignant Red Blood Cell (RBC) Disorders: Sickle Cell, Thal, and DBA: Reduced Intensity C NCT00957931 | Stanford University | Phase 2 |
| Completed | Assessment of Pain in People With Thalassemia NCT00872339 | Carelon Research | — |
| Completed | Sildenafil to Improve Exercise Capacity in People With Thalassemia and Pulmonary Hypertension NCT00872170 | Carelon Research | Phase 2 / Phase 3 |
| Completed | The Spleen in Sickle Cell Anemia and Sickle Cell Thalassemia NCT00971698 | HaEmek Medical Center, Israel | — |
| Completed | Iron Overload and Growth Velocity in Thalassemia and Sickle Cell Anemia NCT00972231 | HaEmek Medical Center, Israel | — |
| Completed | Reduced Intensity Conditioning for Umbilical Cord Blood Transplant in Pediatric Patients With Non-Malignant Di NCT00744692 | Duke University | Phase 1 |
| Completed | Unrelated Hematopoietic Stem Cell Transplantation(HSCT) for Genetic Diseases of Blood Cells NCT00730314 | Children's Hospital Los Angeles | Phase 1 / Phase 2 |
| Unknown | Iron Balance Study of Deferasirox, Deferoxamine and the Combination of Both NCT00738413 | Weill Medical College of Cornell University | Phase 1 / Phase 2 |
| Completed | Oral Nifedipine to Treat Iron Overload NCT00712738 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Phase 1 |
| Completed | Bone Marrow for Hemoglobinopathy Research NCT00669305 | St. Jude Children's Research Hospital | — |
| Completed | Sickle Cell Anemia Screening and Prevention in Northern Israel NCT00735488 | HaEmek Medical Center, Israel | — |
| Completed | Clinical Diagnosis of Teenagers Admitted to Pediatric Departments NCT00735540 | HaEmek Medical Center, Israel | — |
| Completed | Evaluating the Safety and Effectiveness of Decitabine in People With Thalassemia Intermedia NCT00661726 | Carelon Research | Phase 2 |
| Completed | Combined Chelation Therapy in Patients With Transfusion Dependent Thalassemia and Iron Overload NCT00901199 | Elliott Vichinsky | Phase 2 |
| Completed | Phase I Study to Examine the Effect of Deferasirox on Renal Hemodynamics in β-thalassemia Patients With Transf NCT00560820 | Novartis Pharmaceuticals | Phase 1 |
| Completed | Evaluating People With Thalassemia: The Thalassemia Longitudinal Cohort (TLC) Study NCT00661804 | Carelon Research | — |
| Completed | Endocrine and Nutritional Assessment in B Thalassemia Major NCT00456690 | HaEmek Medical Center, Israel | N/A |
| Completed | Pegasys® Plus Ribavirin in Thalassemic Patients With Hepatitis C Virus Infection NCT00707850 | Baqiyatallah Medical Sciences University | Phase 4 |
| Unknown | Detection of β Thalassemia Carriers by Red Cell Parameters Obtained From the H2 Automatic Counter NCT00481221 | HaEmek Medical Center, Israel | — |
| Terminated | Related Hematopoietic Stem Cell Transplantation (HSCT) for Genetic Diseases of Blood Cells NCT02512679 | Children's Hospital Los Angeles | Phase 2 |
| Completed | T2* in Transfusion Dependant Anemia, MI, LVF, Normal Patients NCT00520559 | Imperial College London | — |
| Completed | The Change of Coagulation Markers in Children With β-thalassemia Disease After Stem Cell Transplantation NCT00789516 | Mahidol University | — |
| Completed | Zinc & Bone Health in Thalassemia: The Think Zinc Study NCT00459732 | UCSF Benioff Children's Hospital Oakland | N/A |
| Completed | Invasive Infections in Children With Hemoglobinopathies NCT00456443 | HaEmek Medical Center, Israel | — |
| Completed | Expanded Access of Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron Overl NCT00235391 | Novartis Pharmaceuticals | Phase 3 |
| Unknown | Factors Promoting Increased Rate and Success of Pregnancy in the Thalassemia Population in Toronto NCT00327639 | University Health Network, Toronto | — |
| Completed | L-Glutamine Therapy for Sickle Cell Anemia and Sickle ß0 Thalassemia NCT00125788 | Emmaus Medical, Inc. | Phase 2 |
| Completed | Evaluation of Efficacy of Zoledronic Acid in Patients With Haemoglobin Syndromes (Thalassemia and Sicle Cell A NCT00346242 | Novartis Pharmaceuticals | Phase 4 |
| Completed | Allogeneic Stem Cell Transplantation Following Chemotherapy in Patients With Hemoglobinopathies NCT00153985 | Dana-Farber Cancer Institute | Phase 2 |
| Terminated | L-Glutamine Therapy for Sickle Cell Anemia NCT00586209 | Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center | Phase 2 |
| Terminated | Allogeneic Stem Cell Transplantation, Severe Homzygous 0/+Thalassemia or Sever Variants of Beta 0/+ Thalassemi NCT00578292 | Baylor College of Medicine | N/A |
| Completed | Evaluating the Safety of Two Medications to Treat Hepatitis C in People With Thalassemia (The HepC Study) NCT00502788 | Carelon Research | Phase 2 |
| Completed | A Pilot Study of HSCT for Patients With High-risk Hemoglobinopathy Using a Nonmyeloablative Preparative Regime NCT00427661 | University of Pittsburgh | N/A |
| Completed | Stem Cell Transplant for Hemoglobinopathy NCT00176852 | Masonic Cancer Center, University of Minnesota | Phase 2 / Phase 3 |
| Terminated | Stem Cell Transplantation After Reduced-Dose Chemotherapy for Patients With Sickle Cell Disease or Thalassemia NCT00034528 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 |
| Terminated | Bone Marrow Transplant From Donor Using Less Toxic Conditioning for Patient With High Risk Hemoglobinopathies NCT00040417 | Baylor College of Medicine | Phase 2 |
| Terminated | Bone Marrow Transplant From Related Donor for Patients With High Risk Hemoglobinopathies NCT00040469 | Baylor College of Medicine | Phase 2 |
| Completed | Thalassemia (Cooley's Anemia) Clinical Research Network (TCRN) NCT00000623 | Carelon Research | — |
| Completed | Combination Iron Chelation Therapy NCT00004982 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Phase 1 |
| Completed | Chelation Therapy of Iron Overload With Pyridoxal Isonicotinoyl Hydrazone NCT00000588 | Case Western Reserve University | Phase 2 |
| Completed | Deferoxamine for the Treatment of Hemochromatosis NCT00001203 | National Heart, Lung, and Blood Institute (NHLBI) | — |
| Completed | Evaluation of Subcutaneous Desferrioxamine as Treatment for Transfusional Hemochromatosis NCT00000595 | National Heart, Lung, and Blood Institute (NHLBI) | Phase 2 |